Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD asciminib - BCR-ABL inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04971226 ASC4FIRST (CABL001J12301) Chronic myeloid leukemia, 1st line Phase 3 402 Major Molecular Response (MMR) at week 48 Arm 1: asciminib 80 mg QD Arm 2: Investigator selected TKI including one of the below treatments: -Imatinib 400 mg QD - Nilotinib 300 mg BID - Dasatinib 100 mg QD - Bosutinib 400 mg QD Patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase Target Patients Read-out Milesstone(s) 2024 Publication TBD 125 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation